Alkem Laboratories Limited — Q4 FY26
Alkem delivered a strong Q4 FY26 with revenue of ₹3,633 crore (+14.6% YoY) and EBITDA of ₹517.4 crore (+32.2% YoY), resulting in an EBITDA margin of 14.24% (+184 bps YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
Domestic business to grow 100-150 bps above IPM
Management expects domestic business to continue growing 100-150 bps above IPM growth, with FY26 ending at ~10% growth.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1